GM antibody technology a shot in the arm for Agen
18 February, 2002 by Pete YoungAgen Biomedical is putting an improved version of its 20-year-old cash cow out to graze in fresh pastures.
New drug chews the fat for Metabolic
18 February, 2002 by Melissa TrudingerMelbourne-based Metabolic Pharmaceuticals is claiming early phase clinical trial success with its new obesity drug.
Our clones are safe, says company
18 February, 2002 by Melissa TrudingerMelbourne-based biotech Clone International has distanced itself from a new Japanese study that casts doubt on the safety and usefulness of a cloning technique.
IMB speeds protein research with new tool
18 February, 2002 by Pete YoungA new proteomics research tool that looks like a bar fridge and costs a cool $500,000 is giving a handy competitive edge to Queensland's Institute of Molecular Bioscience.
Fast-moving Antisense making new development links
18 February, 2002 by Tanya HollisNewly listed drug discovery company Antisense Therapeutics has revealed it is tying up relationships with Australian and overseas institutes to develop its discovery pipeline.
Start-up Phenomix shows the way forward
18 February, 2002 by Daniella GoldbergAustralian biotech start-up Phenomix has closed a $US12 million deal with a first-tier Australian/US venture capital syndicate.
